Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.716 SEK | -5.68% | +16.23% | +26.43% |
05-23 | Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy | CI |
05-21 | Transcript : Cantargia AB, Q1 2024 Earnings Call, May 21, 2024 |
- Stock Market
- Equities
- CANTA Stock
- Charts Cantargia AB
- Static Chart